Möchten Sie immer auf dem neuesten Stand bleiben?

LifeMD allegedly overstated its strength and raised 2025 guidance despite rising acquisition costs in RexMD and obesity drugs, misleading investors.

The complaint alleges Savara hid that its MOLBREEVI BLA lacked key data, making FDA approval and timely submission unlikely and raising funding risks.

The complaint alleges Fly-E misled investors about demand and revenue outlook while downplaying battery, supply chain, and regulatory risks

The complaint alleges Savara misled investors by failing to disclose that its MOLBREEVI BLA lacked sufficient FDA data, causing a filing delay.

The complaint alleges Dow overstated its ability to manage macro and tariff headwinds, making its statements about business and prospects misleading.

The complaint alleges LifeMD overstated its strength and raised 2025 guidance without factoring rising customer costs, making its statements misleading.

Dow overstated its ability to handle economic and tariff headwinds while downplaying weak demand, oversupply, and pricing pressures.

Visa allegedly misled investors about its compliance with federal antitrust laws and internal controls, causing investor losses when the truth emerged.

LifeMD allegedly overstated its competitive strength and raised 2025 guidance despite rising customer acquisition costs in key segments.

Savara allegedly misled investors about its MOLBREEVI BLA, which the FDA later refused to file due to missing manufacturing and control data.